Cancer immunotherapy: breaking the barriers to harvest the crop

被引：107

作者：

Pardoll, D ^{[1
]}

Allison, J

机构：

[1] Johns Hopkins Univ, Sch Med, Sidney Kimmel Canc Ctr, Baltimore, MD 21218 USA

[2] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

来源：

NATURE MEDICINE | 2004年 / 10卷 / 09期

基金：

美国国家卫生研究院;

关键词：

D O I：

10.1038/nm0904-887

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Successful translation of modern molecular immunology into effective cancer immunotherapy is threatened by regulatory barriers and challenges to the development of novel agents and combinatorial strategies through effective public-private partnerships. For its promise to be fully realized, both the National Cancer Institute and Food and Drug Administration must take active steps to help academic investigators and companies jointly navigate the pathways from laboratory to clinic.

引用

页码：887 / 892

页数：6

共 20 条

[1]

Akhtar S, 2002, NEW ENGL J MED, V346, P1830

[2] Cancer immunotherapy: A treatment for the masses [J].

Blattman, JN ;

Greenberg, PD .

SCIENCE, 2004, 305 (5681) :200-205

[3] CTLA-4-mediated inhibition in regulation of T cell responses: Mechanisms and manipulation in tumor immunotherapy [J].

Chambers, CA ;

Kuhns, MS ;

Egen, JG ;

Allison, JP .

ANNUAL REVIEW OF IMMUNOLOGY, 2001, 19 :565-594

[4]

Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730

[5]

Dudley ME, 2002, SCIENCE, V298, P850, DOI 10.1126/science.1076514

[6]

Ergenzinger E, 2003, SCIENTIST, V17, P43

[7] Gene transfer: regulatory issues and their impact on the clinical investigator and the good manufacturing production facility [J].

Grilley, BJ ;

Gee, AP .

CYTOTHERAPY, 2003, 5 (03) :197-207

[8] Adjuvant therapy for high-risk primary and resected metastatic melanoma [J].

Hersey, P .

INTERNAL MEDICINE JOURNAL, 2003, 33 (1-2) :33-43

[9]

Levitsky HI, 2000, CANCER J, V6, pS281

[10] Does the immune system see tumors as foreign or self? [J].

Pardoll, D .

ANNUAL REVIEW OF IMMUNOLOGY, 2003, 21 :807-839

← 1 2 →